We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Microincision Surgery Successfully Removes Kidney Cancer

By HospiMedica International staff writers
Posted on 23 Aug 2010
A new study confirms that laparoendoscopic single-site surgery (LESS) is safe and feasible for partial and total kidney removal and the excision of life-threatening tumors and blood clots from the main kidney vein.

Researchers at the University of California, Dan Diego (UCSD; USA) conducted prospective pilot evaluation studies of the LESS procedure for radical and cytoreductive nephrectomy, renal vein thrombectomy, and partial nephrectomy. More...
Ten patients (three men, seven women, mean age 58.7 years) underwent the procedures between February and May of 2009. Patient and tumor characteristics, oncologic features, and SF-36 quality of life (QoL) outcome scores were analyzed.

The results, after a median follow-up 9.8 months, showed that 9 out of 10 cases were completed successfully, and all patients had negative margins. The mean operative time was 161 minutes, estimated blood loss was 125 mL, and the incision size was 4.4 cm. The mean preoperative, three-, and six-month postoperative SF-36 QoL Score was 73.8, 74.4, and 77.1, respectively; all patients are currently alive. The study was published ahead of print on June 7, 2010, in the BioMed Central Urology publication Diagnostic and Therapeutic Endoscopy.

"For advanced as well as localized kidney cancer, our surgical team has been able to reduce and consolidate the number of incisions to one port hidden in the belly button,” said lead author Ithaar Derweesh, M.D., an associate professor of surgery at the UCSD Cancer Center. "With one small opening to deploy instruments and remove diseased tissue, patients benefit from fewer complications, minimal opiate-requirements, preserved quality of life, and excellent short term outcomes.”

LESS is an advanced minimally invasive surgical procedure in which the surgeon operates almost exclusively through a single entry point, typically the patient's navel. Since the entire surgery is performed through it, no visible scar is left, as in a traditional multiport laparoscopic approach. Surgeons employing the LESS technique contend that patients benefit from less postoperative pain, less blood loss, faster recovery time, fewer complications, and better cosmetic results.

Related Links:

University of California, Dan Diego






Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Head Rest
Medifa 61114_3
Mobile X-Ray System
K4W
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.